Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis

Luo, Wanwan; Mao, Panying; Zhang, Lingmin; Chen, Xiaoyu; Yang, Zaixing

doi:10.21037/apm.2020.02.11

Cited by 21 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 10 17 Our result is supported by a recent meta-analysis that did find an association between AMH and SLE among women not treated with CYC, although the authors noted that their pooled results were heavily influenced by one study that showed a very strong association. 31 …”

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone in African-American women with systemic lupus erythematosus

et al. 2020

View full text Add to dashboard Cite

ObjectiveWomen with SLE may experience ovarian insufficiency or dysfunction due to treatment or disease effects. Anti-Müllerian hormone (AMH), a marker of ovarian reserve, has been examined in small populations of women with SLE with conflicting results. To date, these studies have included very few African-American women, the racial/ethnic group at greatest risk of SLE.MethodsWe enrolled African-American women aged 22–40 years diagnosed with SLE after age 17 from the Atlanta Metropolitan area. Women without SLE from the same area were recruited from a marketing list for comparison. AMH was measured in serum using the Ansh Labs assay (Webster, Texas, USA). We considered AMH levels <1.0 ng/mL and AMH <25th percentile of comparison women as separate dichotomous outcomes. Log-binomial regression models estimating prevalence ratios were adjusted for age, body mass index and hormonal contraception use in the previous year.ResultsOur sample included 83 comparison women without SLE, 68 women with SLE and no history of cyclophosphamide (SLE/CYC−) and 11 women with SLE and a history of cyclophosphamide treatment (SLE/CYC+). SLE/CYC+ women had a greater prevalence of AMH <1.0 ng/mL compared with women without SLE (prevalence ratio (PR): 2.90, 95% CI: 1.29 to 6.51). SLE/CYC− women were also slightly more likely to have AMH <1.0 ng/mL (PR: 1.62, 95% CI: 0.93 to 2.82) than comparison women. Results were similar when considering AMH <25th percentile by age of comparison women.ConclusionsTreatment with CYC is associated with low AMH in African-American women with SLE. SLE itself may also be associated with reduced AMH, but to a lesser extent.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone in African-American women with systemic lupus erythematosus

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis of 19 studies analyzing patients with systemic lupus erythematosus concluded that serum AMH levels were significantly lower in patients with systemic lupus erythematosus compared with healthy control participants (pooled standardized mean differences −0.79; 95% CI, −1.41 to −0.18). In addition, AMH levels were further lowered by the immunosuppressant cyclophosphamide (pooled standardized mean differences of −0.58; 95% CI, −0.87 to −0.30) ( 67 ).…”

Section: Assessment Of the For In Autoimmune Diseasesmentioning

confidence: 99%

Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function

Moolhuijsen

Visser

2020

The Journal of Clinical Endocrinology &Amp; Metabolism

328

235

View full text Add to dashboard Cite

Context Anti-Müllerian hormone is produced by granulosa cells of small growing follicles in the ovary. Serum AMH levels strongly correlate with the number of growing follicles, and therefore it has received increasing attention as a marker for ovarian reserve. This review summarizes recent findings and limitations in the application of serum AMH in ovarian reserve assessment. Evidence acquisition A PubMed search was conducted to find recent literature on the measurements and use of serum AMH as a marker for ovarian reserve. Evidence synthesis Serum AMH levels are measured to assess the ‘functional ovarian reserve’, a term that is preferred over ‘ovarian reserve’, since AMH levels reflect the pool of growing follicles which potentially can ovulate. Serum AMH levels are used in individualized FSH dosing protocols and may predict the risk of poor response or OHSS, but has limited value in predicting ongoing pregnancy. Serum AMH levels are studied to predict natural or disease-related age of menopause. Studies show that the age-dependent decline rates of AMH vary among women. The generalized implementation of serum AMH measurement has also lead to an increase in diagnostic assays, including automated assays. However, direct comparison of results remains problematic. Conclusion Serum AMH remains the preferred ovarian reserve marker. However, the lack of an international standard for AMH limits comparison between AMH assays. Furthermore, still little is known about endogenous and exogenous factors that influence serum AMH levels, which limits proper interpretation of AMH values in a clinical setting.

show abstract

“…Одни исследователи утверждают, что у женщин с СКВ, получающих комбинированную терапию цитостатиками и ЦФ, уровень АМГ значительно ниже, чем у пациенток находящихся на монолечении ЦФ и другими иммунодепрессантами. В то же время ряд авторов выявил прямую корреляцию кумулятивной дозы ЦФ и МТ с низким уровнем AMГ [11,14,16,17]. C. Di Mario и соавт.…”

Section: клиническое наблюдениеunclassified

“…Так, W. Luo и соавт. [11] на основании результатов исследования предположили, что активность СКВ может быть взаимосвязана с сывороточным уровнем AMГ. Другими исследователями обнаружено более выраженное снижение уровня АМГ в сыворотке крови у больных СКВ по сравнению с общей популяцией [12][13][14].…”

unclassified

See 1 more Smart Citation

Anti-Mullerian hormone in systemic lupus erythematosus

Alekberova¹,

Егорова²,

Goloeva³

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Currently, in patients with systemic lupus erythematosus (SLE) increasing attention is paid to the ovarian reserve evaluation, which can serve as one of the markers of a favorable response to therapy and pregnancy planning. For this purpose, anti-Mullerian hormone (AMH) is considered as the most sensitive marker, that reflect the continuous growth of small follicles. The article presents data on the relationship of serum hormone levels with age, ethnicity, body weight, disease activity, and therapy. We present clinical cases of three women of childbearing age with SLE, different duration of the disease and cumulative dose of disease-modifying antirheumatic drugs in whom the level of AMH in the blood serum was measured.

show abstract

Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis

Cited by 21 publications

References 29 publications

Anti-Müllerian hormone in African-American women with systemic lupus erythematosus

Anti-Müllerian hormone in African-American women with systemic lupus erythematosus

Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function

Anti-Mullerian hormone in systemic lupus erythematosus

Contact Info

Product

Resources

About